CRMD - CorMedix surges as FDA says no advisory meeting required for Defencath application

CorMedix (CRMD) shares climbs 14% in premarket , after the company said the FDA has decided to cancel the Antimicrobial Drug Advisory Committee meeting tentatively scheduled for January 14, 2021, to discuss the marketing application for Defencath, to be used as a catheter lock solution in hemodialysis patients for the prevention of catheter related blood stream infections.The company was notified that based on the agency’s ongoing dialogue with CorMedix, discussion at an advisory committee is not needed, and it will continue to work on the application with the company during the remainder of the review cycle.Agency's action remains February 28, 2021.

For further details see:

CorMedix surges as FDA says no advisory meeting required for Defencath application